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Abstract
Background: Pressure sores are important and common complications of spinal cord injury. Many
preventive and therapeutic approaches have been tried and new trials are evolving. One relatively recent
method is application of a hydrocolloid dressing (HD). In this study we compared the therapeutic effects
of HD on pressure ulcer healing with two other topical applications, phenytoin cream (PC) and simple
dressing (SD).
Methods: Ninety-one stage I and stage II pressure ulcers of 83 paraplegic male victims of the Iran-Iraq
war were randomly allocated to three treatment groups. Mean age and weight of the participants were
36.64 ± 6.04 years and 61.12 ± 5.08 kg, respectively. All the patients were managed in long term care units
or in their homes for 8 weeks by a team of general practitioners and nurses, and the ulcer status was
recorded as "Complete healing", "Partial healing", "Without improvement" and "Worsening".
Results: Complete healing of ulcers, regardless of location and stage, was better in the HD group than
the PC [23/31(74.19%) vs 12/30(40%); difference: 34.19%, 95% CI = 10.85–57.52, (P < 0.01)] or the SD
[23/31(74.19%) vs 8/30(26.66%); difference: 47.53%, 95% CI = 25.45–69.61, (P < 0.005)] groups. Complete
healing of stage I ulcers in the HD group [11/13(85%)] was better than in the SD [5/11(45%); difference:
40%, 95% CI = 4.7–75.22, (P < 0.05)] or PC [2/9 (22%); difference: 63%, 95% CI = 29.69–96.3, (P < 0.005)]
groups. Complete healing of stage II ulcer in the HD group [12/18 (67%)] was better than in the SD group
[3/19(16%); difference: 51%, 95% CI = 23.73–78.26, (P < 0.005)], but not significantly different from the
PC group [10/21 (48%); difference: 19%, 95% CI = -11.47–49.47, (P > 0.05)]. We performed a second
analysis considering only one ulcer per patient (i.e. 83 ulcers in 83 patients). This "per patient" analysis
showed that complete ulcer healing in the HD group was better than in the PC [20/28(71.4%) vs 11/28
(39.3%); difference: 32.1%, 95% CI = 7.4–56.7, (P < 0.01)] or SD [20/28(71.4%) vs 8/27 (29.6%); difference:
41.8%, 95% CI = 17.7–65.8, (P < 0.005)] groups.
Conclusion: We deduced that HD is the most effective method investigated for treating stage I and II
pressure ulcers in young paraplegic men.
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Background
Skin ulcers caused by pressure and strains are known by
various names: decubitus ulcer, bedsore, ischemic ulcer
and pressure ulcer. "Pressure ulcer", which indicates the
etiology of the lesion, seems the most appropriate name
[1]. An estimated 50–80% of individuals suffering from
spinal cord injury develop pressure ulcers at least once in
their lifetime. Most of these ulcers occur during the first
two years after injury, but even after 3–4 years an inci-
dence of 30% has been reported [2-4].
Although the major challenge is to prevent the occurrence
of ulcers [5,6], therapeutic measures merit due attention.
Pressure ulcer therapy is among the expensive of medical
and surgical interventions [5-7]. In one study in the
United Kingdom, data relating to chronic wound manage-
ment practice obtained from 15 pressure sore studies
showed a cost range of 422–2548 pounds per healed
wound for primary dressing, nursing time, wound cleans-
ing and debridements [8]. These figures do not include
the much higher costs of hospitalization and plastic sur-
gery. We have tried to find a more effective and cost-effi-
cient method of treatment.
Different methods have been used for preventing and
treating pressure ulcers. These include various training
programs for patients [4,9,10]; physiotherapy methods
employing ultrasound, ultraviolet irradiation and laser
treatment [7]; good nutrition emphasizing high protein,
high calorie diet and more liquid; electrical stimulation;
and application of local ointments and creams such as
bacitracin, silver sulfadiazine, neomycin, polymixin,
phenytoin and hydrocolloid dressings [11-19].
The results of the studies conducted so far are incompati-
ble, even contradictory. Most of them considered too few
patients and/or lacked a control group. In Iran, 5000
patients suffer from spinal cord injury (SCI): of these,
2000 are lran-lraq war victims and 3000 were handi-
capped by other causes. In view of the enormous preva-
lence of pressure ulcers in war victims and other spinal
handicap patients, and the importance of these lesions in
terms of morbidity, mortality and cost of treatment, we
have compared the efficacies of applying hydrocolloid
dressing, phenytoin cream and a simple dressing. The
aims were to determine: 1. which is the most effective in
terms of complete ulcer healing; 2. whether healing rates
differ with respect to the ulcer stage (I and II) or location
(gluteal, ischial, sacral) using these three different
methods.
Methods
The study was a randomized single blind clinical trial
involving 2015 Iranian spinal cord injury (SCI) victims of
the Iran-Iraq war (1980–1988). The SCI victims were
accessed through the mediation and assistance of the
Jaonbazan Medical and Engineering Research Center
(JMERC) http://www.jmerc.ac.ir, the medical and
research section of the official governmental body respon-
sible for SCI war victims. The study proposal was
reviewed, approved and granted by JMERC.
The medical records of all 2015 subjects were studied to
identify cases with pressure ulcers. Where the data were
unknown or unreliable, the patients were visited at home
or in victims' long term care centers. Finally, 165 pressure
ulcers in 151 patients were identified. All relevant data
including patient age and weight, the longevity of the
ulcer before our intervention, and the size, stage and loca-
tion of the ulcer, were collected by the general practition-
ers in the team. Next, all the patients were examined by
one of the authors to confirm their eligibility for the
study. The eligibility criteria were: A) Inclusion Criteria: 1.
Paraplegia caused by spinal cord injury; 2. Pressure ulcer
stage I and II according to Shea classification [20] or
National Pressure Ulcer Advisory Panel [21] (Fig. 1); 3.
Patient's informed consent; 4. Smoothness of ulcer area to
establish whether adhesive could be used at the site.
Exclusion criteria: 1. Addiction; 2. Heavy smoking (more
than 20 cigarettes a day or more than 10 packs per year; 3.
Concomitant chronic disease (e.g. diabetes mellitus or
frank vascular disease such as Buerger's disease).
Seventy-four ulcers in 68 patients were excluded because
they did not meet these eligibility criteria: 31 ulcers (28
patients) were stage III or higher; 27 ulcers (25 patients)
were excluded because of patient's smoking/addiction; 5
ulcers (5 patients) had uneven surfaces; 4 ulcers (4
patients) were excluded because of systemic diseases; and
6 patients with 7 ulcers refused to participate (Fig. 2).
Thus, the study sample comprised 83 patients with 91
pressure ulcers in the ischial, sacral or gluteal areas. These
91 ulcers were allocated to three different groups (30
ulcers each) by stratified randomization. Three therapeu-
tic methods were applied as follow: simple dressing (SD),
hydrocolloid dressing (HD), and adhesive and phenytoin
cream (PC). Two general practitioners and nine nurses
trained in treatment interventions administered the
protocols.
The SD patients were visited twice a day, the PC patients
once a day and the HD patients twice a week. All partici-
pants were visited and examined in their family homes or
nursing homes by general practitioners every two weeks to
ensure that the treatments were being properly applied
and were consistent among the three groups. There were
no differences in the facilities available for patients in
family homes versus nursing homes, and all the patients
had free access to victims' long term care centers.BMC Dermatology 2004, 4:18 http://www.biomedcentral.com/1471-5945/4/18
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In the SD group, the following steps were taken twice a
day. The ulcer was cleaned and washed 3 times with nor-
mal saline, then dried with a sterile gauze and, depending
on the size of ulcer, covered with wet saline gauze dress-
ing. In the PC group, daily dressing and cleaning of ulcer
were similar to the SD group, except that a thin layer of
phenytoin cream was applied to the ulcer before the dress-
ing was performed. In the HD group, after the ulcer had
been cleaned in a similar manner to the SD group, the
hydrocolloid adhesive dressing was applied to the ulcer
area. The adhesive dressings were changed twice a week.
Any necrotic tissue was debrided before treatment; all
debridements preceded ulcer tracing and assignment of
the participants to the trial groups. No debridement was
allowed after treatment had started. No concomitant top-
ical or systemic antibiotic, glucocorticoid or
Two pressure ulcer classifications Figure 1
Two pressure ulcer classifications.
Shea Classification  National Pressure Ulcer Advisory Panel 
1. Limited to epidermis, exposing 
dermis;  includes a red area 
Stage I:  Non-blanchable erythema 
of intact skin; the heralding lesion of 
skin ulceration 
2. Full-thickness of dermis to the 
junction of subcutaneous fat 
Stage II: Partial thickness skin loss 
involving epidermis and/or dermis. 
The ulcer is superficial and presents 
clinically as an abrasion, blister, or 
shallow crater 
3. Fat obliterated limited by the deep 
fascia undermining of skin 
Stage III: Full thickness skin loss 
involving damage or necrosis of 
subcutaneous tissue which may 
extend down to, but not through, 
underlying fascia. The ulcer 
presents clinically as a deep crater 
with or without undermining of 
adjacent tissue. 
4. Bone at the base of ulceration  Stage  IV:  Full  thickness  skin  loss  with 
extensive destruction, tissue necrosis or 
damage to muscle, bone or supporting 
structures (e.g., tendon, joint capsule, etc) 
5. Closed large cavity through a small 
sinusBMC Dermatology 2004, 4:18 http://www.biomedcentral.com/1471-5945/4/18
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Flow diagram of participants through each stage of the study Figure 2
Flow diagram of participants through each stage of the study.
151 patients
(165 pressure ulcers) 
were assessed for 
eligibility
68 patients (74 ulcers) 
were excluded:
62 patients (67 ulcers) 
did not meet inclusion 
criteria
6 patients (7 ulcers) 
refused to participate 83 patients 
(91 ulcers) 
randomized
(stratified)
27 patients 
(30 ulcers) 
 allocated to simple
dressing
28 patients 
(30 ulcers) allocated 
to phenytoin 
28 patients
(31 ulcers) allocated 
to hydrocolloid 
dressing
0 lost to  8 wks 
follow-up
0 lost to 8 wks 
follow-up
0 lost to 8 wks 
follow-up
27 patients
(30 ulcers) included
in the analysis
28 patients
(30 ulcers) included
in the analysis
28 patients 
(31 ulcers) included in 
the analysis
Sampled population 
n= 2015 SCI *  patients
*SCI: spinal cord injury BMC Dermatology 2004, 4:18 http://www.biomedcentral.com/1471-5945/4/18
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immunosuppressive agent was allowed during the treat-
ment period. Fortunately, none of our patients needed
debridement or the aforementioned concomitant thera-
pies during the study period. There were no differences
among the trial groups with respect to other concomitant
care measures.
Every two weeks a questionnaire regarding the ulcer's sta-
tus was completed by the general practitioners; and at the
end of 8 weeks, the ulcers' conditions were examined
blind by one author and assessed as "Complete Healing",
"Partial Healing", "Without Improvement" or "Worsen-
ing". To measure each ulcer's surface area, the ulcer bor-
ders were traced on to a paper overlay. This primary
schematic representation was then scanned, redrawn and
measured by AutoCAD 2000 software.
The primary outcome was whether or not the ulcer was
completely healed within 8 weeks. "Complete ulcer heal-
ing" was defined as: A) For stage I ulcer, intact epidermis,
no red area; B) For stage II ulcers, intact dermis and epi-
dermis, no abrasion or ulceration. Other definitions were
as follows. "Partial healing" = any decrease in ulcer size
compared to the baseline ulcer tracing, excluding com-
plete healing. "Without improvement" = no change in
ulcer size compared to the baseline ulcer tracing. "Wors-
ening" = any increase in ulcer size compared to the base-
line ulcer tracing. The difference in responses between
patients receiving HD and patients receiving the other
therapies (PC or SD) were determined [22].
Before the study, we assumed response rates of 30%, 40%
and 80% for SD, PC and HD, respectively. Thus, based on
the 40% difference, power of 0.85, 95% confidence level
and estimated follow-up loss of 10%, 29 patients were
required for each study group. The number of ulcers that
met the eligibility criteria totaled 91 and all were enrolled
in the study.
A random-number table was used to generate the random
allocation sequence, and stratified randomization was
used to achieve balance between the treatment groups and
subgroups (ulcer stages and locations). If a patient had
more than one ulcer, all the ulcers were treated by the
same method to eliminate the possible complicating fac-
tor of treatment interactions. The statistician in the team
generated the random allocation sequence. He was
informed of the patient list (numbers only) and the ulcer
stage and location of each patient.
The treatment category for each patient was determined
by the statistician and was delivered in an opaque sealed
envelope bearing only the number of the patient. These
sealed envelopes were delivered to the general practition-
ers, along with the list of patients' numbers and names.
After each patient was visited, the appropriately num-
bered envelope was opened by the general practitioner to
determine whether the SD, PC or HD method would be
used, then the appropriate intervention commenced.
The authors were blind to the patients' assignment to trial
groups. The general practitioners were also blind to the
treatment of each patient up to the start of the study, when
they opened the sealed envelopes. After intervention
began, both the general practitioners and the nurses knew
the trial groups, because significant differences among the
three treatment methods precluded blinding. The patients
were also aware of the treatment methods, although they
initially had equal chances of entering any of the trial
groups. Thus, the study was single-blinded and the author
who enrolled the patients to the study was blind to treat-
ment assignment. The author who finally assessed the
outcomes was also blind to the trial group of each patient.
To maintain the blinded status on assessment of out-
comes, the assessor examined the patients, after the ulcer
dressings had been removed by the general practitioners,
with no knowledge of the trial groups to which they had
Table 1: Baseline characteristics of study subjects assigned to hydrocolloid, phenytoin and simple dressing groups
Variables Mean Age 
Of patients 
(yr ± SD)
Mean weight 
Of patients 
(kg ± SD)
Mean duration 
of ulcer before 
treatment (wk ± 
SD)
Mean ulcer size 
(cm2 ± SD)
Stage of ulcer 
(no)
Treatment group; no II I
Total n = 83 patients 91 ulcers 36.64 ± 6.04 61.12 ± 5.08 6.25 ± 6.56 7.54 ± 12.99 33 58
Hydrocolloid n = 28 patients 31 ulcers 36.81 ± 6.71 62.26 ± 5.44 7.63 ± 5.59 7.26 ± 15.4 13 18
Phenytoin n = 28 patients 30 ulcers 36.5 ± 4.99 60.07 ± 4.39 5.84 ± 8.04 5.12 ± 3.63 9 21
Simple dressing n = 27 patients 30 ulcers 36.6 ± 6.17 61 ± 5.03 5.25 ± 5.39 10.27 ± 15.32 11 19
P-Value of comparing variables of 3 groups P > 0.10 P > 0.10 P > 0.10 P > 0.10 P > 0.62BMC Dermatology 2004, 4:18 http://www.biomedcentral.com/1471-5945/4/18
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been assigned. The gross appearance of the ulcers without
dressing, whether healed or not, did not indicate the trial
group. The assessor was asked during the 8-week outcome
assessment to try to identify which treatment has been
administered to each patient. Overall, 27.7% of his
guesses were correct (25% in the HD group, 32.1% in the
PC group and 25.9% in the SD group), so they were were
no better than chance; i.e. there were no significant differ-
ences among the three trial groups with respect to propor-
tions guessed correctly (P > 0.2 in all cases).
The study proposal was designed in November 2001, and
the recruitment of patients began in March 2002 and
lasted about 2 months. Then the patients were allocated to
the treatment groups and followed-up for another 2
months. Finally, all the collected data were analyzed
within 2 months. Thus the study from proposal to final
analysis took about 10 months (November 2001-Septem-
ber 2002). At the end of the study, all the data collected
from the patients' preliminary and complementary ques-
tionnaires were analyzed by SPSS software using ANOVA
and Chi square tests, and P-values of <0.05 were assumed
significant. The 95% confidence intervals were also calcu-
lated and reported [23]. For rare events (more than 20 per-
cent of cross tabulation cells had values less than 5),
Fisher's exact test was used. Based on stage and location of
ulcers, subgroup analyses were performed using the same
statistical tests.
Results
Ninety-one ulcers in 83 male patients were treated by one
of three methods. The mean age and weight of the patients
were 36.64 ± 6.04 years and 61.12 ± 5.08 kg, respectively.
Of the 91 ulcers, 33 were stage I and the remaining 58
were stage II. There were no significant differences among
the three therapeutic groups in baseline demographic
characteristics (table 1) or in ulcer location (sacral, glu-
teal, ischial) or stage (I or II) (Fig. 3 and 4).
The numbers of ulcers and the degree of improvement in
the three therapeutic groups are shown in table 2. The
completion of healing, regardless of location and stage,
was better in the HD than in the PC [23/31(74.19%) vs
12/30(40%); difference 34.19%, 95% CI = 10.85–57.52,
(P < 0.01)] or the SD [23/31(74.19%) vs 8/30(26.66%);
difference 47.53%, 95% CI = 25.45–69.61, (P < 0.005)]
groups. Completion of healing of stage I ulcers in the HD
group [11/13(85%)] was also better than in the SD [5/
11(45%); difference 40%, 95% CI = 4.7–75.22, (P <
0.05)] or PC [2/9 (22%); difference 63%, 95% CI =
29.69–96.3, (P < 0.005)] groups. Completion of healing
of stage II ulcers was better in the HD group [12/18(67%)]
Table 2: Healing status of pressure ulcers in 3 treatment groups (hydrocolloid, phenytoin and simple dressing)
healing status Complete Partial Not improved Worsened Total
Treatment group; no (%)
Hydrocolloid n = 31 23 (74.19%) 4 (12.58%) 2 (6.45%) 2 (6.45%) 31 (100%)
Phenytoin n = 30 12 (40%) 4 (13.33%) 12 (40%) 2 (6.66%) 30 (100%)
Simple dressing n = 30 8 (26.66%) 5 (16.66%) 8 (26.66%) 9 (30%) 30 (100%)
Ulcer distribution according to treatment group and location Figure 3
Ulcer distribution according to treatment group and location.
Ulcer distribution according to treatment group and stage Figure 4
Ulcer distribution according to treatment group and stage.
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than in the SD group [3/19(16%); difference 51%, 95%
CI = 23.73–78.26, (P < 0.005)], but there was no signifi-
cant difference from the PC group [10/21 (48%); differ-
ence 19%, 95 CI = -11.47–49.47, (P > 0.05)].
Gluteal ulcers healed more completely in the HD group
[6/6(100%)] than in the PC [2/7 (29%); difference 71%,
95% CI = 37.38–100, (P < 0.005)] or SD [1/8(13%); dif-
ference 87%, 95% CI = 63.69–100, (P < 0.001)] groups.
The corresponding figures for ischial ulcers were: HD
group 13/18(72%) and SD group 3/14 (21%); difference
51%, 95% CI = 21.2–80.7, (P < 0.005)]. The PC group was
not significantly different from HD: 8/18(44%); differ-
ence 28%, 95% CI = -2.9–58.9, (P < 0.1)]. In the case of
sacral ulcers, complete healing in HD group did not differ
significantly from either of the others. The results were:
HD group 4/7 (57%), SD group 4/8(50%); difference 7%,
95% CI = -50–64.15, (P > 0.35), and PC group 2/5(40%);
difference 17%, 95% CI = -39.4–73.4, (P > 0.20)].
We performed a second analysis on 83 ulcers in 83
patients. We selected one ulcer per patient using a random
number table; 31 of the 83 ulcers were stage I and the
remaining 52 were stage II. There were again no signifi-
cant differences among the trial groups with respect to
baseline characteristics (table 3). This "per patient" analy-
sis showed that complete ulcer healing, regardless of
location and stage, in the HD group was better than in the
PC [20/28(71.4%, 95% CI = 54.7–88.1) vs 11/28 (39.3%,
95% CI:21.3–57.3); difference 32.1%, 95% CI = 7.4–56.7,
(P < 0.01)] or SD [20/28(71.4%, 95% CI = 54.7–88.1) vs
8/27 (29.6%, 95% CI = 12.4–46.8); difference 41.8%,
95% CI = 17.7–65.8, (P < 0.005)] groups.
All completely healed ulcer patients were followed up by
monthly visits from general practitioners for a further 4
months after the end of the trial. They were also examined
by the assessor author. No recurrence of ulceration was
observed in any of the trial groups during this period.
All patients completed the study and there were no losses
to follow up, no treatment withdrawals, no trial group
changes and no major adverse events (Fig. 2).
Discussion
Diphenyl hydantoin sodium (phenytoin) is an effective
anti-epileptic medication. Its capacity to accelerate ulcer
healing was reported more than 40 years ago [24]. Since
then, it has been used topically for different kinds of
wounds and ulcers such as war wounds, sores caused by
venous stasis, atrophic ulcers and burns, and positive
effects have been reported [25-27]. Possible mechanisms
of action of phenytoin cream on wound healing are as fol-
lows: 1. Decrease in serum corticosteroid; 2. Acceleration
of assembly and presence of collagen and fibrin in the
ulcer area, and stimulation of alkaline phosphatase secre-
tion [28].
The use of HD for healing pressure ulcers dates from
about 20 years ago. The benefits of this method in com-
parison with conventional methods include reduction of
bacterial contamination, facilitation of patient move-
ment, improvement in patient's psychological condition,
more convenience and less pain [29-34]. Hydrocolloid
adhesive dressings absorb water and low molecular
weight components from ulcer secretions, so they swell to
produce a jelly. This jelly protects the ulcer, and new cells
proliferate [35]. Moreover, the jelly stimulates the
immune system locally by activating granulocytes, mono-
cytes and the complement system [36], decreasing the
effects of bacterial colonization and ensuring autodebri-
dement of the ulcer [1].
Bacterial colonization is likely under the HD layer and is
responsible for the unpleasant aroma detected when the
dressings are changed, but it should not be misinterpreted
as clinical infection. In fact, clinical trials of HD on more
than 2000 ulcers have shown a much lower incidence of
infection than in other treatment methods [29,30,33].
Table 3: Baseline characteristics of study subjects assigned to three trial groups considering the patient as unit of analysis(one ulcer 
per patient).
Variables Mean duration of ulcer 
before treatment (wk ± 
SD)
Mean ulcer size (cm2 ± 
SD)
Stage of ulcer (no)
Treatment group; no I II
Total n = 83 5.92 ± 6.27 7.78 ± 13.53 31 52
Hydrocolloid n = 28 7.12 ± 5.68 7.47 ± 16.4 12 16
Phenytoin n = 28 6.11 ± 8.4 5.13 ± 3.67 9 19
Simple dressing n = 27 4.47 ± 3.64 10.84 ± 16.32 10 17
P-Value P > 0.20 P > 0.20 P > 0.70BMC Dermatology 2004, 4:18 http://www.biomedcentral.com/1471-5945/4/18
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Thus, the ulcer dry-out method is not considered as useful
as it once was, and the current trend is towards a damp
method using HD [37-41].
In this study, the therapeutic effects of HD on gluteal and
ischial ulcers were shown to be superior to those of PC
and SD. In view of the cost of pressure ulcer management
in hospitals and sanitariums and the high expense of plas-
tic surgery [42], and the psychological problems associ-
ated with paralysis and pressure management in SCI
victims [35,43,44], it seems rational to shift to simpler
methods that are more cost efficient and executable by the
individual patient [31,34,35]. HD treatment of pressure
ulcers is less expensive and more comfortable and will
ultimately increase the patients' self-confidence [8,45].
These adhesives are available in different sizes and brands
convenient for use in ulcers of different parts of body. In
the most recent products, the appropriate time for
changing the adhesive is indicated by a color conversion.
In addition, their transparency makes it easy to observe
the ulcer's status without removing the adhesive and
dressing [46].
Although the therapeutic effects of HD on sacral ulcers, in
contrast to gluteal and ischial ulcers, did not appear in this
survey to be significantly better (p > 0.05) than phenytoin
and simple dressings, nor was it less effective. Whether the
lesser healing effect of HD on sacral ulcers corresponds to
the pressure effects in this area, or to greater bacterial col-
onization or other factors [3,4,6,47], needs to be clarified
by further studies.
Gross differences among the three treatment modalities
precluded double blinding. Blinding the authors to the
treatment groups minimized this limitation. The major
tasks, i.e. defining the study population, enrolling the par-
ticipants who met the eligibility criteria and assessing the
primary and secondary outcomes, were performed blind
by the authors. To reduce differences in baseline demo-
graphic characteristics among the treatment groups and
subgroups and to minimize losses to follow-up, war-
related SCI patients were recruited and all the patients
who met the eligibility criteria were enrolled in the study.
They were all relatively young males (mean age 36.64 ±
6.04 years) and had good motivation to complete the
course of treatment. The results of this trial cannot be
extrapolated to stage III or stage IV pressure ulcers or to
other types of wounds. Furthermore, the small numbers
of gluteal and sacral ulcers preclude definitive statements
about differences among the treatment subgroups.
Conclusion
The observed efficacy of HD in the treatment of pressure
ulcers suggests that it might be effectively applied to other
stage I or stage II pressure ulcers.
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